MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Eccogene
Study ID
NCT07505303
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Adult Obesity
  • Weight Management

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • ECC4703 — DRUG
    orally QD
  • Placebo — DRUG
    orally QD
  • Semaglutide — DRUG
    SC once weekly

Study Details

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Key Dates

Start date
Mar 23, 2026
Status verified
Jun 2026
Primary completion
Oct 15, 2026
Completion
Oct 15, 2026

Study Design

Enrollment
151 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1: ECC4703 + semaglutide
    ECC4703 orally QD + semaglutide SC once weekly
  • Placebo Comparator: Arm 2: Placebo + semaglutide
    Placebo orally QD + semaglutide SC once weekly

Primary Outcome Measure

Percentage Change in Body Weight from Baseline (Week 9) to Week 20 [ Time Frame: Baseline (Week 9) to Week 20 ]

Locations (15)

Find similar trials in Birmingham, AL

Related Studies